LYR-210
Phase 3Small molecule
LYR-210 is one of 69 small molecule programs targeting Sinusitis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
94 competitors in Sinusitis
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Mucinex
AAultman Health Foundation
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Oxycontin
PProtega
Approved
Rayos
RRoxane Laboratories
Approved
Zocor
OOrganon and Co
Approved
Asmanex
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Rhinosinusitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LYR-210. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLyra Therapeutics